ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Toon Van Gorp, David Cibula, Weiguo Lv(Women's Hospital, School of Medicine, Zhejiang University), Floor Backes, Fırat Ortaç, K. Hasegawa, Kristina Lindemann, Antonella Savarese, Annouschka Laenen, Y.M. Kim(University of Ulsan), Lisa M. Bodnar, M-P Barretina-Ginesta, L. Gilbert, Bhavana Pothuri, Xiaojun Chen, Marcelo B.S. Flores(Fundación Arturo López Pérez), Tally Levy, N. Colombo, Christos Papadimitriou, Tommy Buchanan, L.C. Hanker, Gemma Eminowicz, L Rob, D. Black, Jasmine Lichfield(MSD (UK) Limited (United Kingdom)), Gen Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Orlowski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen J. O’Keefe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alain Lortholary, Brian M. Slomovitz
Cited by 81
Abstract
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al.|JNCI Journal of the National Cancer Institute|1993|15.9k